系统性红斑狼疮的激素依赖性与癌症
这项西班牙多中心回顾性队列研究纳入3539例系统性红斑狼疮(SLE)患者,分析首次患癌后的癌症发生率及相关因素,并按激素敏感(HS)与非HS癌症分类。结果显示SLE患者总体癌症标准化发病比(SIR)为1.37,65岁以下女性更高(SIR 2.38);非HS癌症可能与累积损伤及ACE抑制剂使用相关。
要点
- SLE患者总体癌症SIR为1.37,65岁以下女性达2.38。
- HS癌症SIR为1.02,非HS癌症SIR为1.93,升高可能主要来自非HS癌症。
- 非HS癌症与SLICC/ACR损伤指数(OR 1.27)及ACE抑制剂处方(OR 2.87)相关。
核心结论
- SLE患者癌症发生率高于西班牙普通人群,尤其在年轻女性中更为明显。
- 该升高可能由非HS癌症驱动,后者与累积损伤更高及更多ACE抑制剂处方相关。
研究设计与样本
- 西班牙风湿病学会SLE注册队列的回顾性多中心研究,纳入3539例患者(90.4%为女性)。
- 分析SLE诊断后首次癌症,收集临床与社会人口学信息、累积损伤、严重度、合并症、治疗及难治性,并将癌症分为HS(前列腺、乳腺、子宫内膜、卵巢)与非HS。
- 计算标准化发病比(SIR)并构建逻辑回归模型。
主要发现
- 154例患者发生癌症(91%为女性),其中44例为HS癌症(100%为女性)。
- 总体癌症SIR为1.37(95%CI 1.15-1.59),65岁以下女性SIR为2.38(95%CI 1.84-2.91)。
- 女性HS癌症SIR为1.02(95%CI 0.13-1.91),非HS癌症SIR为1.93(95%CI 0.98-2.89)。
- HS与非HS癌症中,SLE诊断年龄(OR 1.04,P=0.002 vs OR 1.04,P=0.019)及疾病演变期(OR 1.01,P<0.001 vs OR 1.00,P=0.029)均与癌症相关。
- 非HS癌症与SLICC/ACR损伤指数(OR 1.27,P=0.022)及ACE抑制剂处方(OR 2.87,P=0.048)相关。
关键数值与推荐
- 癌症分类:HS包括前列腺、乳腺、子宫内膜和卵巢癌;非HS为其余癌症。
- 总体癌症SIR 1.37(95%CI 1.15-1.59);65岁以下女性SIR 2.38(95%CI 1.84-2.91)。
- 女性HS癌症SIR 1.02(95%CI 0.13-1.91);非HS癌症SIR 1.93(95%CI 0.98-2.89)。
临床怎么用
- 对SLE患者,尤其年轻女性,应关注癌症筛查与监测。
- 非HS癌症风险可能与累积损伤及ACE抑制剂使用相关,临床需综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the incidence and analyze any cancer-associated factors in patients with systemic lupus erythematosus (SLE), differentiating between hormone-sensitive (HS) and non-HS cancers. METHODS: This was a retrospective multicenter study of a patient cohort from the Systemic Lupus Erythematosus Registry of the Spanish Society of Rheumatology. Included were the first cancer post-SLE diagnosis, clinical and sociodemographic information, cumulative damage, severity, comorbidities, treatments, and refractoriness. Cancers were classified as HS (prostate, breast, endometrium, and ovarian) and non-HS (the remainder). The standardized incidence ratio (SIR) was calculated and logistic regression models were built. RESULTS: A total of 3,539 patients (90.4% women) were included, 154 of whom had cancer (91% female), and 44 had HS cancer (100% female). The cancer SIR was 1.37 (95% confidence interval [95% CI] 1.15-1.59), with higher values in women age <65 years (SIR 2.38 [95% CI 1.84-2.91]). The SIR in women with HS versus non-HS cancer was 1.02 (95% CI 0.13-1.91) and 1.93 (95% CI 0.98-2.89). In HS versus non-HS cancers, SLE diagnostic age (odds ratio [OR] 1.04 [P = 0.002] versus 1.04 [P = 0.019]), and period of disease evolution (OR 1.01 [P < 0.001] versus 1.00 [P = 0.029]) were associated with cancer. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (OR 1.27 [P = 0.022]) and angiotensin-converting enzyme (ACE) inhibitor prescriptions (OR 2.87 [P = 0.048]) were associated with non-HS cancers. CONCLUSION: Cancer incidence in patients with SLE was higher than in the Spanish population, particularly among young women. This increase might be due to non-HS cancers, which would be associated with SLE involving greater cumulative damage where more ACE inhibitors are prescribed.
引用
- Cobo-Ibáñez T, Urruticoechea-Arana A, Rúa-Figueroa I, et al. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020. PMID: 31529686. doi:10.1002/acr.24068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。